Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
121,975
189,683
261,770
281,769
218,113
248,967
Depreciation, Depletion & Amortization
64,304
65,474
69,188
63,791
64,863
63,458
Other Funds
664
743
3,736
3,841
1,083
60,724
Funds from Operations
233,904
172,459
239,869
270,575
257,348
251,700
Changes in Working Capital
16,325
17,518
76,665
33,345
57,115
9,728
Net Operating Cash Flow
217,579
189,977
316,534
237,230
314,463
261,428
Capital Expenditures
56,146
81,166
118,117
48,648
40,285
Sale of Fixed Assets & Businesses
27,244
5,450
1,753
1,262
1,209
Purchase/Sale of Investments
5,949
6,156
15,998
28,158
6,277
Net Investing Cash Flow
30,173
73,767
149,847
75,001
123,648
Cash Dividends Paid - Total
58,656
62,146
69,615
70,119
71,634
Net Financing Cash Flow
89,395
121,118
193,478
166,153
203,429
Net Change in Cash
126,461
5,057
36,401
19,107
9,193
Free Cash Flow
188,318
165,818
283,022
208,220
289,386
Net Assets from Acquisitions
-
-
42,653
50,915
83,723
Change in Capital Stock
30,075
58,229
120,127
92,193
130,712
Exchange Rate Effect
28,450
9,965
9,610
15,183
3,421
Other Uses
7,220
4,207
6,828
4,858
7,125

About Astellas Pharma

View Profile
Address
2-5-1 Nihonbashi-Honcho
Tokyo Tokyo 103
Japan
Employees -
Website http://www.astellas.com
Updated 07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.